Atopic dermatitis results from a combination of skin barrier damage and a skewed immune response to epicutaneously presented allergens. The inflammatory response is dynamic. Keratinocytes shape the immune response through the secretion of cytokines and contribute to the recruitment of lymphocytes by releasing chemokines. The initial Th2 response is important for the IgE production and supports a mastocytic and eosinophilic inflammation while later on other lymphocytic populations (Th1, Th17, and Th22) play a role. TARC = Thymus and activation-regulated chemokine. TSLP = Thymic stromal lymphopoietin.
Relationship between drug exposure and inhibition of cytokine function. The blue line shows the concentration of oclacitinib needed to inhibit the listed Janus kinase 1 (JAK1)–dependent cytokines. The potency of oclacitinib toward cytokines can be illustrated by generating dose-response curves that show the inhibitory effects of increasing concentrations of oclacitinib on cytokine function. Half maximal inhibitory concentration (IC50) can be determined from these curves, indicating the concentration of oclacitinib that inhibits the function of that cytokine by 50%. (Adapted from Incorporating Apoquel® chewable tablets into practice. In: Clinician’s Forum, a Clinician’s Brief supplement; 2022. Sponsored by an educational grant from Zoetis. Reprinted with permission from Embark Veterinary, Inc.) Revolution Medicine For Dogs
Atopic dermatitis results from a combination of skin barrier damage and a skewed immune response to epicutaneously presented allergens. The inflammatory response is dynamic. Keratinocytes shape the immune response through the secretion of cytokines and contribute to the recruitment of lymphocytes by releasing chemokines. The initial Th2 response is important for the IgE production and supports a mastocytic and eosinophilic inflammation while later on other lymphocytic populations (Th1, Th17, and Th22) play a role. TARC = Thymus and activation-regulated chemokine. TSLP = Thymic stromal lymphopoietin.
Relationship between drug exposure and inhibition of cytokine function. The blue line shows the concentration of oclacitinib needed to inhibit the listed Janus kinase 1 (JAK1)–dependent cytokines. The potency of oclacitinib toward cytokines can be illustrated by generating dose-response curves that show the inhibitory effects of increasing concentrations of oclacitinib on cytokine function. Half maximal inhibitory concentration (IC50) can be determined from these curves, indicating the concentration of oclacitinib that inhibits the function of that cytokine by 50%. (Adapted from Incorporating Apoquel® chewable tablets into practice. In: Clinician’s Forum, a Clinician’s Brief supplement; 2022. Sponsored by an educational grant from Zoetis. Reprinted with permission from Embark Veterinary, Inc.)
Gonzales AJ , Bowman JW , Fici GJ , et al . Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy . J Vet Pharmacol Ther . 2014 ; 37 ( 4 ): 317 – 324 . doi: 10.1111/jvp.12101
Collard WT , Hummel BD , Fielder AF , et al . The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog . J Vet Pharmacol Ther . 2014 ; 37 ( 3 ): 279 – 285 . doi: 10.1111/jvp.12087
Cosgrove SB , Wren JA , Cleaver DM , et al . Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis . Vet Dermatol . 2013 ; 24 ( 5 ): 470-e114 . doi: 10.1111/vde.12047
Banovic F , Tarigo J , Gordon H , Barber JP , Gogal RM Jr . Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production . Vet Dermatol . 2018 ; 30 ( 1 ): 17-e6.5 . doi: 10.1111/vde.12698
Jasiecka-Mikołajczyk A, Jaroszewski JJ, Maślanka T.Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro.Res Vet Sci .2018 ;121 : 124 – 129 .doi: 10.1016/j.rvsc.2018.10.014
Jasiecka-Mikołajczyk A , Jaroszewski JJ , Maślanka T . Oclacitinib, a janus kinase inhibitor, reduces the frequency of IL-4- and IL-10-, but not IFN-γ-, producing murine CD4+ and CD8+ T cells and counteracts the induction of type 1 regulatory T cells . Molecules . 2021 ; 26 ( 18 ): 5655 . doi: 10.3390/molecules26185655
Rugg CA , Mccandless EE , Messamore JE , Gonzales AJ . Oclacitinib (Apoquel) inhibits allergen-induced production of interleukin-31 but not interferon-gamma or interleukin-4 in canine Th2 cells . Vet Dermatol . 2014 ; 25 : 389 .
Herrmann I , Mamo LB , Holmes J , Mohammed JP, Murphy KM , Bizikova P . Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-β, in dogs with atopic dermatitis . Vet Dermatol . In press . doi: 10.1111/vde.13140
Hensel P , Santoro D , Favrot C , Hill P , Griffin C . Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification . BMC Vet Res . 2015 ; 11 : 196 . doi: 10.1186/s12917-015-0515-5
Cosgrove SB , Cleaver DM , King VL , et al . Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life . Vet Dermatol . 2015 ; 26 ( 3 ): 171-e35 . doi: 10.1111/vde.12194
Little PR , King VL , Davis KR , Cosgrove SB , Stegemann MR . A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs . Vet Dermatol . 2015 ; 26 ( 1 ): 23-e8 . doi: 10.1111/vde.12186
Gadeyne C , Little P , King VL , Edwards N , Davis K , Stegemann MR . Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia . Vet Dermatol . 2014 ; 25 ( 6 ): 512-e86 . doi: 10.1111/vde.12166
Denti D , Caldin M , Ventura L , De Lucia M . Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs Vet Dermatol . 2022 ; 33 ( 2 ): 149-e42 . doi: 10.1111/vde.13053
Cosgrove SB , Wren JA , Cleaver DM , et al . A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis . Vet Dermatol . 2013 ; 24 :( 6 ): 587-e142 . doi: 10.1111/vde.12088
Gonzales AJ , Fleck TJ , Humphrey WR , et al . IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics . Vet Dermatol . 2016 ; 27 ( 1 ): 34-e10 . doi: 10.1111/vde.12280
Souza CP , Rosychuk RAW , Contreras ET , Schissler JR , Simpson AC . A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA . Vet Dermatol . 2018 ; 29 ( 6 ): 489-e164 . doi: 10.1111/vde.12682
Michels GM , Walsh KF , Kryda KA , et al . A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis . Vet Dermatol . 2016 ; 27 ( 6 ): 505-e136 . doi: 10.1111/vde.12364
Marsella R , Ahrens K , Wilkes R , Trujillo A , Dorr M . Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs . Vet Dermatol . 2020 ; 31 ( 4 ): 284-e69 . doi: 10.1111/vde.12849
Gotthelf LN . Efficacy of Apoquel for the control of otitis externa secondary to allergic skin disease in client-owner dogs . Int J Vet Health Sci Res . 2017 ; 5 ( 7 ): 208 – 212 .
US Food and Drug Administration . Apoquel FOI. Accessed December 1, 2022. http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM363901.pdf
Lancellotti B , Angus J , Edginton H , Rosenkrantz WS . Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib . J Am Vet Med Assoc . 2020 ; 257 ( 5 ): 507 – 516 . doi: 10.2460/javma.257.5.507
Simpson A , Schissler J , Rosychuk R , Moore R . The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study . Vet Dermatol . 2017 ; 28 ( 5 ): 485-e113 . doi: 10.1111/vde.12450
Zoetis . Apoquel® film-coated tablets for dogs . Zoetis Belgium SA ; 2018 .
Rynhoud H , Gibson JS , Meler E , Soares Magalhães RJ . The association between the use of oclacitinib and antibacterial therapy in dogs with allergic dermatitis: a retrospective case-control study . Front Vet Sci . 2021 ; 8 : 631443 . doi: 10.3389/fvets.2021.631443
Marsella R , Ahrens K . A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs . Vet Dermatol . 2018 ; 29 ( 5 ): 439-e146 . doi: 10.1111/vde.12660
Papp KA , Bissonnette R , Gooderham M , et al . Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial . BMC Dermatol . 2016 ; 16 ( 1 ): 15 . doi: 10.1186/s12895-016-0051-4
Sivaraman P , Cohen SB . Malignancy and Janus kinase inhibition . Rheum Dis Clin North Am . 2017 ; 43 ( 1 ): 79 – 93 . doi: 10.1016/j.rdc.2016.09.008
Harrison CN , Vannucchi AM , Kiladjian JJ , et al . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis . Leukemia . 2016 ; 30 ( 8 ): 1701 – 1707 . doi: 10.1038/leu.2016.148
Bronden LB , Eriksen T , Kristensen AT . Mast cell tumors and other skin neoplasia in Danish dogs–data from the Danish Veterinary Cancer Registry . Acta Vet Scand . 2010 ; 52 ( 1 ): 6 . doi: 10.1186/1751-0147-52-6
De Mello Souza CH , Shiomitsu K , Hwang B . Cytokine production and the effects of oclacitinib in three canine mast cell tumour lines . Vet Dermatol . 33 ( 2 ): 159-e46 , 2021 . doi: 10.1111/vde.13046
Santoro D , Marsella R , Hernandez J . Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study . Vet Dermatol . 2007 ; 18 ( 2 ): 101 – 106 . doi: 10.1111/j.1365-3164.2007.00582.x
High EJ , Lam A , Ferrer L . A retrospective study comparing the incidence of cutaneous histiocytoma development in atopic dogs treated with oclacitinib and ciclosporin. Abstracts of the North American Veterinary Dermatology Forum 26–29 April 2017 Orlando, FL, USA . Vet Dermatol . 2017 ; 28 : 426 – 455 . doi: 10.1111/vde.12452
Noli C , Matricoti I , Schievano C . A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with non-flea nonfood-induced hypersensitivity dermatitis . Vet Dermatol . 2019 ; 30 ( 2 ): 110-e30 . doi: 10.1111/vde.12720
Lopes NL , Campos DR , Machado MA , et al . A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats . BMC Vet Res . 2019 ; 15 ( 1 ): 137 . doi: 10.1186/s12917-019-1893-x
Ortalda C , Noli C , Colombo S , Borio S . Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats . Vet Dermatol . 2015 ; 26 ( 4 ): 235-e53 . doi: 10.1111/vde.12218
Carrasco I , Ferrer L , Puigdemont A . Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response . J Feline Med Surg . 2022 ; 24 ( 8 ): 787 – 793 . doi: 10.1177/1098612X211048458
Ferrer L, Carrasco I, Cristofol C, Puigdemont A.A pharmacokinetic study of oclacitinib maleate in six cats.Vet Dermatol.2020;31 ( 2 ): 134 – 137 .doi: 10.1111/vde.12819
Foster SF , Charles JA , Canfield PJ , Beatty JA , Martin P . Reactivated toxoplasmosis in a FIV-positive cat . Aust Vet Pract . 1998 ; 28 : 159 – 163 .
Collard W , Thorn J , Smith S , et al . Pharmacokinetics of oclacitinib following oral and intravenous administration to horses. 2020 ACVIM Forum on Demand Research Abstract Program . J Vet Int Med . 2020 ; 34 : 2979 .
Moore A , Burrows A , Malik R , Ghubash RM , Last RD , Remaj B . Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome . Vet Dermatol . 2022 ; 33 ( 5 ): 435 – 439 . doi: 10.1111/vde.13097
Barrs VR , Martin P , Beatty JA . Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy . Aust Vet J . 2006 ; 84 ( 1−2 ): 30 – 35 . doi: 10.1111/j.1751-0813.2006.tb13119.x
Evans NA , Walker JM , Manchester A , Bach JF . Acute respiratory distress syndrome and septic shock in a cat with disseminated toxoplasmosis . J Vet Emerg Crit Care (San Antonio) . 2017 ; 27 ( 4 ): 472 – 478 . doi: 10.1111/vec.12621
Last RD , Suzuki Y , Manning T , Lindsay D , Galipeau L , Whitbread T . A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin for feline atopy . Vet Dermatol . 2004 ; 15 ( 3 ): 194 – 198 . doi: 10.1111/j.1365-3164.2004.00371.x
Hunyadi L , Datta P , Rewers-Felkins K , et al . Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses . J Vet Pharmacol Ther . 2022 ; 45 ( 3 ): 320 – 324 . doi: 10.1111/jvp.13043
Visser M , Cleaver D , Cundiff B , King V , Sture G . Oclacitinib maleate (Apoquel) dose determination in horses with naturally occurring allergic dermatitis. 2020 ACVIM Forum on Demand Research Abstract Program . J Vet Int Med . 2020 ; 34 : 2977 – 2978 .
Levy BJ , Linder KE , Olivry T . The role of oclacitinib in the management of ischaemic dermatopathy in four dogs . Vet Dermatol . 2019 ; 30 ( 3 ): 201-e63 . doi: 10.1111/vde.12743
Pulsoni D , Friere A , Ferreira R . Juvenile-onset ischaemic dermatopathy in two dogs treated with oclacitinib. Abstracts of the 30th Annual Congress of the ECVD-ESVD, 2018, Dubrovnik, Croatia . Vet Dermatol . 2018 ; 29 : 371 .
Cousandier G , Scholten AD , Scotton G , Stefanello C . Juvenile-onset ischemic dermatopathy in a dog . Acta Sci Vet . 2021 ; 49 . doi: 10.22456/1679-9216.105583
Aymeric E , Bensignor E . A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib . Vet Dermatol . 2017 ; 28 ( 5 ): 512-e123 . doi: 10.1111/vde.12458
Martinez N , McDonald B , Crowley A . A case report of the beneficial effect of oclacitinib in a dog with pemphigus vulgaris . Vet Dermatol . 2022 ; 33 ( 3 ): 237-e65 . doi: 10.1111/vde.13063
Colombo S , Cornegliani L , Vercelli A , Fondati A . Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series . Vet Dermatol . 2021 ; 32 ( 4 ): 363-e100 . doi: 10.1111/vde.12992
High EJ , Linder KE , Mamo LB , Levy BJ , Herrmann I , Bizikova P . Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs . Vet Dermatol . 2020 ; 31 ( 4 ): 330-e86 . doi: 10.1111/vde.12852
Leonard C , Van Soens I , Fontaine J . Inherited sensory and autonomic neuropathy in a border collie, interest of oclacitinib for the control of self-mutilation . Vet Sci . 2022 ; 9 ( 3 ): 127 . doi: 10.3390/vetsci9030127
Anderson T , Schissler J . Assessment of oclacitinib as a treatment for canine chronic idiopathic rhinitis using a validated rhinitis scoring instrument: a retrospective study. Abstracts of the 2019 North American Veterinary Dermatology Forum . Vet Dermatol . 2019 ; 30 : 277 – 306 . doi: 10.1111/vde.12750
de Oliveira JK , Williams DL , Bollmann C , de Seabra NM , Bortolini M , Montiani-Ferreira F .Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca .Vet Ophthalmol .2019 ;22 ( 5 ): 633–643.doi: 10.1111/vop.12634
Carrasco I, Martínez M, Albinyana G.Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus.Vet Dermatol.2021 ;32 (3): 299 – 301.doi:10.1111/vde.12949
Tomich LM , Pieper JB . Urticaria pigmentosa-like skin disease in a domestic shorthair cat . JFMS Open Rep . 2019 ; 5 ( 1 ): 2055116918821197 .
Aslan J , Shipstone MA , Sullivan LM . Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report . Vet Dermatol . 2021 ; 32 ( 4 ): 398-e113 . doi: 10.1111/vde.12976
Barrett LE , Gardner HL , Barber LG , Sadowski A , London CA . Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study . BMC Vet Res . 2019 ; 15 ( 1 ): 291 . doi: 10.1186/s12917-019-2032-4
Thomas SJ , Snowden JA , Zeidler MP , Danson SJ . The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours . Br J Cancer . 2015 ; 113 ( 3 ): 365 – 371 . doi: 10.1038/bjc.2015.233
Lu Z , Hong CC , Jark PC , et al . JAK1/2 inhibitors AZD1480 and CYT387 inhibit canine B-cell lymphoma growth by increasing apoptosis and disrupting cell proliferation . J Vet Intern Med . 2017 ; 31 ( 6 ): 1804 – 1815 . doi: 10.1111/jvim.14837
Revolution Cat Medication Drake GJ , Nuttall T , López J , et al . Treatment success in three Andean bears ( Tremarctos ornatus) with alopecia syndrome using oclacitinib maleate (APOQUEL®) . J Zoo Wildl Med . 2017 ; 48 ( 3 ): 818 – 828 . doi: 10.1638/2016-0239.1